Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RIT1 oncoproteins escape LZTR1-mediated proteolysis
Pau Castel, Alice Cheng, Antonio Cuevas-Navarro, et al.
Science (2019) Vol. 363, Iss. 6432, pp. 1226-1230
Open Access | Times Cited: 96

Showing 1-25 of 96 citing articles:

RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore, Scott Rosenberg, Frank McCormick, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 8, pp. 533-552
Open Access | Times Cited: 819
The RASopathies: from pathogenetics to therapeutics
Katie E. Hebron, Edjay R. Hernandez, Marielle E. Yohe
Disease Models & Mechanisms (2022) Vol. 15, Iss. 2
Open Access | Times Cited: 117
Rare molecular subtypes of lung cancer
Guilherme Harada, Soo‐Ryum Yang, Emiliano Cocco, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 229-249
Open Access | Times Cited: 73
LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases
Taiki Abe, Ikumi Umeki, Shin‐ichiro Kanno, et al.
Cell Death and Differentiation (2019) Vol. 27, Iss. 3, pp. 1023-1035
Open Access | Times Cited: 101
Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition
Daichi Inoue, Jacob T. Polaski, Justin Taylor, et al.
Nature Genetics (2021) Vol. 53, Iss. 5, pp. 707-718
Open Access | Times Cited: 82
Defining RASopathy
Katherine A. Rauen
Disease Models & Mechanisms (2022) Vol. 15, Iss. 2
Open Access | Times Cited: 61
The molecular genetics of RASopathies: An update on novel disease genes and new disorders
Marco Tartaglia, Yoko Aoki, Bruce D. Gelb
American Journal of Medical Genetics Part C Seminars in Medical Genetics (2022) Vol. 190, Iss. 4, pp. 425-439
Open Access | Times Cited: 43
Intronic CRISPR Repair in a Preclinical Model of Noonan Syndrome–Associated Cardiomyopathy
Ulrich Hanses, Mandy Kleinsorge, Lennart Roos, et al.
Circulation (2020) Vol. 142, Iss. 11, pp. 1059-1076
Open Access | Times Cited: 66
Ubiquitin ligases in cancer: Functions and clinical potentials
Shanshan Duan, Michele Pagano
Cell chemical biology (2021) Vol. 28, Iss. 7, pp. 918-933
Open Access | Times Cited: 50
Post-translational modification of RAS proteins
Sharon L. Campbell, Mark R. Philips
Current Opinion in Structural Biology (2021) Vol. 71, pp. 180-192
Open Access | Times Cited: 50
Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights
Xinchen Tian, Tinghao Yan, Fen Liu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 36
Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition
Wei Wei, Mitchell J. Geer, Xinyi Guo, et al.
The Journal of Experimental Medicine (2023) Vol. 220, Iss. 5
Open Access | Times Cited: 21
RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity
Pau Castel, Srisathiyanarayanan Dharmaiah, Matthew J. Sale, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 33
Open Access | Times Cited: 33
New prospectives on treatment opportunities in RASopathies
Bruce D. Gelb, Marielle E. Yohe, Cordula M. Wolf, et al.
American Journal of Medical Genetics Part C Seminars in Medical Genetics (2022) Vol. 190, Iss. 4, pp. 541-560
Open Access | Times Cited: 24
Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation
Sisi Chen, Rahul S. Vedula, Antonio Cuevas-Navarro, et al.
Cancer Discovery (2022) Vol. 12, Iss. 10, pp. 2434-2453
Open Access | Times Cited: 23
RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome–associated cardiac hypertrophy
Antonio Cuevas-Navarro, Morgan E. Wagner, Richard Van, et al.
Science Advances (2023) Vol. 9, Iss. 28
Open Access | Times Cited: 13
Preclinical evaluation of CRISPR-based therapies for Noonan syndrome caused by deep-intronic LZTR1 variants
Carolin Knauer, Henrike Haltern, Eric Schoger, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 1, pp. 102123-102123
Open Access | Times Cited: 5
The sixth international RASopathies symposium: Precision medicine—From promise to practice
Karen W. Gripp, Lisa Schill, Lisa Schoyer, et al.
American Journal of Medical Genetics Part A (2019) Vol. 182, Iss. 3, pp. 597-606
Open Access | Times Cited: 38
DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis
Bárbara Rivera, Javad Nadaf, Somayyeh Fahiminiya, et al.
Journal of Clinical Investigation (2019) Vol. 130, Iss. 3, pp. 1479-1490
Open Access | Times Cited: 37
Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer
Athea Vichas, Amanda K. Riley, Naomi T. Nkinsi, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 32
Mutation-induced LZTR1 polymerization provokes cardiac pathology in recessive Noonan syndrome
Alexandra Viktoria Busley, Óscar Gutiérrez‐Gutiérrez, Elke Hammer, et al.
Cell Reports (2024) Vol. 43, Iss. 7, pp. 114448-114448
Open Access | Times Cited: 4
Nerve Enlargement in Patients with INF2 Variants Causing Peripheral Neuropathy and Focal Segmental Glomerulosclerosis
Tran Thuy Huong Quynh, Linh Tran, Hiroko Ueda, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 127-127
Open Access
RIT1 Promotes the Proliferation of Gliomas Through the Regulation of the PI3K/AKT/c‐Myc Signalling Pathway
Zhen Liu, Hao‐dong Jiang, Hao‐yuan Kan, et al.
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 2
Open Access
Oncogenic RIT1 mutations confer ferroptosis vulnerability in lung adenocarcinoma
Ruilan Ma, Dian Yang, Peng Wang, et al.
Biology Direct (2025) Vol. 20, Iss. 1
Open Access
The tumor suppressor LZTR1: Its expression, purification and characterization
Yifang Sun, Yuxuan Jiang, Meng Zhang, et al.
Protein Expression and Purification (2025), pp. 106716-106716
Closed Access
Page 1 - Next Page

Scroll to top